Novo Nordisk eyes over five blockbuster drug launches by 2030
Novo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at a Capital Markets Day in London.
LONDON, Sept 21 (Reuters) — Novo Nordisk is targeting the launch of more than five blockbuster drugs by 2030 and expects pipeline sales of more than 150 billion Danish crowns, or $23 billion, in 2035, CEO Mike Doustdar said at a Capital Markets Day in London. 5096 Danish crowns. Reporting by Patrick Wingrove, writing by Louise Rasmussen; Editing by Emelia Sithole-Matarise. com; +45 21 27 97 79.